Interferon Gamma in Cancer Immunotherapy

Introduction to Interferon Gamma and Cancer Immunotherapy

Cancer develops through the progressive accumulation of genetic mutations and disruptions in normal cellular regulatory mechanisms. These alterations enable abnormal cells to proliferate uncontrollably, evade programmed cell death, and escape immune surveillance. The immune system is capable of distinguishing not only between self and foreign pathogens, but also between healthy cells and transformed cancerous cells. This biological capability forms the foundation of cancer immunotherapy.

Over the past decade, cancer immunotherapy has become one of the most effective therapeutic approaches in oncology. Immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 pathways have demonstrated significant clinical success in multiple cancer types. Several studies have shown that these therapies stimulate the production of interferon gamma (IFNγ), a cytokine that plays a central role in antitumor immune responses. Increased IFNγ signaling contributes directly to tumor cell destruction, enhancement of immune cell activity, and modulation of the tumor microenvironment.

Recent research has further demonstrated that resistance to immunotherapy is frequently associated with defects in IFNγ signaling pathways. These findings indicate that the therapeutic efficacy of modern immunotherapies is strongly linked to the activation and regulation of IFNγ-mediated immune responses.

Structure and Signaling Mechanisms of IFNγ

Interferon gamma was initially identified because of its antiviral activity observed in vitro. IFNγ belongs to the type II interferon family and exerts its biological functions through binding to a receptor complex composed of two subunits: IFNGR1 and IFNGR2.

Once IFNγ binds to its receptor, intracellular signaling cascades are activated through Janus kinases JAK1 and JAK2. This activation subsequently induces phosphorylation of STAT1 and activation of interferon regulatory factor 1 (IRF1). Activated STAT1 and IRF1 migrate into the nucleus, where they regulate the transcription of multiple IFNγ-responsive genes involved in immune regulation, inflammation, antigen presentation, and tumor suppression.

This signaling network plays an essential role in cancer immunology by coordinating both innate and adaptive immune responses against malignant cells. IFNγ signaling is therefore considered a critical component of effective tumor immunosurveillance and immunotherapeutic activity.

IFNγ Expression in the Tumor Microenvironment

IFNγ is primarily produced by activated T lymphocytes and natural killer (NK) cells following exposure to inflammatory or immune stimuli. Within tumors, tumor-infiltrating lymphocytes (TILs) represent one of the major sources of IFNγ production. The presence of IFNγ-producing immune cells within tumors is strongly associated with improved immune surveillance and better clinical outcomes in several cancer types.

Regulation of IFNγ Production by Tumor Conditions

The tumor microenvironment contains several factors capable of regulating IFNγ expression. One major inhibitory factor is lactate acidosis, which is commonly observed in malignant tissues due to increased tumor glycolysis. Elevated lactate levels and reduced pH can significantly suppress IFNγ production by NK cells. Studies in lymphoma models have shown that restoration of physiological pH levels through systemic alkalization can recover NK cell IFNγ secretion and improve immune activity within tumors.

Epigenetic mechanisms also contribute to IFNγ regulation in cancer. In lung cancer patients, hypermethylation of the IFNγ promoter region in CD4+ T cells is associated with reduced IFNγ expression. Tumor cells can induce DNA methyltransferase activity in immune cells, leading to transcriptional silencing of the IFNγ gene and weakening antitumor immunity.

MicroRNAs additionally influence IFNγ production. MicroRNA-155 (miR-155) has been identified as a positive regulator of IFNγ expression within tumors. Increased miR-155 expression enhances IFNγ production by T cells and contributes to tumor regression. Conversely, transcription factors such as Twist1 negatively regulate IFNγ expression by interfering with transcriptional activators including Runx3 and T-bet.

Clinical Importance of IFNγ in Cancer Patients

The expression profile of IFNγ has important prognostic and predictive significance in clinical oncology. In patients treated with PD-L1 inhibitors such as durvalumab, elevated IFNγ-related gene signatures correlate with improved therapeutic responses and longer progression-free survival.

In melanoma and non-small cell lung cancer (NSCLC), higher IFNγ expression after PD-1 inhibitor treatment is associated with better immunotherapy outcomes. These observations suggest that IFNγ may serve as a valuable biomarker for predicting responsiveness to immune checkpoint blockade therapies.

However, the prognostic value of IFNγ can vary depending on tumor type, cancer stage, and interactions with other immune molecules such as PD-L1. Therefore, IFNγ signaling must be interpreted within the broader context of the tumor immune microenvironment.

Antitumor Functions of IFNγ

IFNγ Enhances Radiotherapy Efficacy

Radiotherapy remains a standard treatment modality for many cancers. Recent evidence indicates that IFNγ is required for optimal radiotherapy-induced antitumor immunity. Experimental studies have demonstrated that ionizing radiation stimulates T-cell-mediated tumor destruction in an IFNγ-dependent manner.

In mouse tumor models, radiotherapy significantly reduces tumor burden in wild-type animals but loses effectiveness in IFNγ-deficient mice. These findings highlight the critical contribution of IFNγ to radiation-induced immune activation.

Direct Inhibition of Tumor Cell Proliferation

IFNγ exerts direct antiproliferative effects on cancer cells through multiple mechanisms, including:

  • Cell cycle arrest
  • Apoptosis induction
  • Necroptosis activation
  • Autophagy stimulation

In breast cancer, colorectal cancer, and hepatocellular carcinoma, IFNγ increases the expression of cell cycle inhibitors such as p21, p27Kip1, and p16. These proteins suppress tumor cell proliferation and promote growth arrest.

In melanoma, IFNγ induces expression of miR-29a and miR-29b, which target cyclin-dependent kinase 6 (CDK6) and inhibit cell cycle progression. IFNγ also promotes reactive oxygen species (ROS)-mediated apoptosis in colorectal cancer cells through activation of cytosolic phospholipase A2 pathways.

Effects of IFNγ on Tumor Vasculature

Beyond direct tumor cell targeting, IFNγ also affects tumor blood vessels and stromal components. IFNγ signaling in endothelial cells can induce vascular regression, reduce blood flow within tumors, and trigger ischemic tumor necrosis.

This antiangiogenic effect contributes significantly to tumor elimination, especially in large established tumors that rely heavily on vascular support for continued growth and metastasis.

Activation of Immune Cells by IFNγ

IFNγ strongly enhances the activity of multiple immune cell populations involved in tumor destruction.

Activation of Antigen-Presenting Cells

IFNγ stimulates antigen-presenting cells (APCs) to increase:

  • MHC molecule expression
  • Antigen processing capacity
  • IL-12 and IL-18 secretion
  • CD86 costimulatory molecule expression

These changes improve T-cell activation and strengthen cytotoxic immune responses against cancer cells.

Enhancement of Cytotoxic T Cell Function

IFNγ signaling promotes differentiation and activation of CD8+ cytotoxic T lymphocytes and Th1 cells. Loss of IFNγ responsiveness in T cells weakens antitumor immunity and facilitates tumor persistence.

Reprogramming of Tumor-Associated Macrophages

Tumor-associated macrophages (TAMs) are often polarized toward an immunosuppressive M2 phenotype that promotes tumor progression and angiogenesis. IFNγ can reprogram TAMs toward the pro-inflammatory M1 phenotype, resulting in:

  • Reduced VEGF production
  • Enhanced tumor cell killing
  • Increased antigen presentation
  • Elevated nitric oxide production

This macrophage re-education contributes significantly to immune-mediated tumor elimination.

Protumor and Immune Escape Functions of IFNγ

Although IFNγ has potent antitumor properties, prolonged or dysregulated IFNγ signaling can paradoxically support tumor immune escape and progression.

Induction of Immune Checkpoint Molecules

One of the most important protumor effects of IFNγ is the induction of immune checkpoint molecules such as PD-L1 and CTLA-4.

IFNγ strongly stimulates PD-L1 expression on tumor cells and surrounding stromal cells. Elevated PD-L1 levels inhibit T-cell activation and allow cancer cells to evade immune destruction.

Similarly, IFNγ can induce CTLA-4 expression in melanoma cells, potentially contributing to immune suppression within tumors.

Promotion of Tumor Immune Tolerance

IFNγ also induces expression of indoleamine 2,3-dioxygenase 1 (IDO1), an immunosuppressive enzyme involved in tryptophan metabolism. High IDO1 expression promotes tumor immune tolerance, suppresses T-cell responses, and contributes to tumor dormancy.

In tumor-repopulating cells, IFNγ-induced IDO1 signaling activates the AhR pathway and p27-mediated mechanisms that protect tumor cells from apoptosis.

Induction of Angiogenesis and EMT

Under certain conditions, IFNγ contributes to tumor progression by enhancing epithelial-mesenchymal transition (EMT), tumor invasion, and angiogenesis.

Studies in papillary thyroid cancer have shown that IFNγ promotes migratory and invasive tumor behavior. IFNγ can also suppress TNFSF15 expression in endothelial cells, thereby facilitating tumor vascularization.

Modulation of Immunosuppressive Myeloid Cells

IFNγ can enhance inducible nitric oxide synthase (iNOS) expression in monocytic myeloid-derived suppressor cells (MDSCs), increasing their immunosuppressive activity and weakening cytotoxic T-cell responses.

These findings demonstrate the dual nature of IFNγ signaling in cancer biology.

IFNγ in Cancer Therapy and Clinical Applications

Several clinical trials are currently investigating IFNγ as a therapeutic agent either alone or in combination with chemotherapy, radiotherapy, immune checkpoint inhibitors, or targeted therapies.

Combination strategies involving IFNγ with cyclophosphamide, cisplatin, or PD-1/PD-L1 inhibitors have demonstrated promising antitumor activity in selected cancers, including ovarian cancer and melanoma.

Despite its strong immunological importance, IFNγ has not yet received broad FDA approval for cancer treatment due to its complex dual role in both tumor elimination and tumor immune escape.

Future Perspectives of IFNγ-Based Immunotherapy

A better understanding of IFNγ signaling dynamics within the tumor microenvironment is essential for optimizing future immunotherapy strategies. Current research focuses on:

  • Combining IFNγ modulation with checkpoint blockade
  • Targeting IFNγ resistance pathways
  • Reducing IFNγ-mediated immune suppression
  • Identifying predictive IFNγ biomarkers
  • Personalizing immunotherapy according to IFNγ signatures

Future therapeutic approaches may involve selective amplification of beneficial IFNγ antitumor functions while minimizing mechanisms that promote immune evasion and tumor progression.

Conclusion

Interferon gamma is a central regulator of cancer immunity and plays a critical role in both tumor suppression and tumor escape mechanisms. IFNγ enhances immune cell activation, promotes tumor cell death, inhibits angiogenesis, and improves responses to modern immunotherapies. However, persistent IFNγ signaling can also induce immune checkpoint expression, immune tolerance, and adaptive tumor resistance.

The dual biological functions of IFNγ highlight the complexity of tumor-immune interactions and emphasize the importance of balanced immune regulation in cancer treatment. Continued investigation into IFNγ-mediated pathways will improve the design of next-generation cancer immunotherapies and support the development of more effective and personalized anticancer strategies.